Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. - Wikidata - awgldk - TriplyDB

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

http://www.wikidata.org/entity/Q44261800

about

Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred Diagnosis and therapy of non-variceal upper gastrointestinal bleeding Current perspectives in NSAID-induced gastropathy NSAIDs: gastroprotection or selective COX-2 inhibitor?Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study An economic model of long-term use of celecoxib in patients with osteoarthritis The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks A review of the gastrointestinal safety data--a gastroenterologist's perspective.Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care Patient benefit-risk in arthritis--a rheumatologist's perspective.Prevention of chronic NSAID induced upper gastrointestinal toxicity.Recent advances in peptic ulcer bleeding.Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care.Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage.Nephrotoxicity related to new therapeutic compounds.Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness FK-3000 isolated from Stephania delavayi Diels. inhibits MDA-MB-231 cell proliferation by decreasing NF-κB phosphorylation and COX-2 expression.An evidence-based update on nonsteroidal anti-inflammatory drugs.Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?

P2860

Q24203871-44129D88-9D85-442D-A9E9-4C6FBCB1D7AF Q24248627-86D2D366-ACC3-4C83-AD70-B359FFBD7A4E Q24804373-07FA9068-6190-40E2-9DC7-22F1BBE6EA9D Q26777626-B59789E6-4ADD-4BBC-B57D-6791104CAF8D Q26827673-CCA769F3-C326-47C6-9AAC-38FF9605C91F Q28168965-459FA9BB-4477-416E-A340-4C82DEB6F02E Q28191928-00641CD4-E9DE-44A5-91E4-51D8A9AA3B47 Q28196933-4582BA7B-FB61-43DB-94DE-A00098070B3E Q28200569-3DD29256-5F54-45B4-AA7A-26F55073BFA5 Q28200571-BFC699BA-D68E-43F9-9DAE-E3C42584E31A Q28200864-35EFEC69-B643-4DE3-B4C4-41AECEF6A222 Q28210656-1DA232D5-029B-45D1-894C-4662F628F10F Q28211313-91425517-B619-4C6F-B5CA-FACBFA73445D Q28218005-4EC9973C-9457-45AB-B31C-416C5F19DECE Q28219195-7086D8FA-3487-4220-97CC-5CFC23E096D1 Q28219634-68862AF8-C42C-46F3-8801-C12AA2BC9750 Q28219972-2655FD84-A206-44E3-82A6-B3B073D549C1 Q28222253-AF179578-CAAF-4005-892E-6F5942457186 Q30430170-FE2011E7-DC09-4281-98F3-501DDF4EA393 Q30629677-B6F7180C-BB38-448F-947F-778866BF4199 Q33560647-48D17FAB-BE81-402C-94E7-3CFB86D5E8CB Q33675386-3D1D8949-ADDA-4DAD-9EEF-2B80BB4D4E7B Q33803037-8F8B0EC6-7DEE-4590-A05C-7E6062FFC0F0 Q33978682-39BEE696-4145-4758-8EC1-8FE9BFDA37CE Q34076408-BA39208B-CFB7-44AB-A9C2-CB15684304FF Q34203458-07AA56EA-9857-414D-B698-7BB844077C64 Q34305332-43F1296A-75A9-407D-ADB5-EC9C86399963 Q34387174-D5735729-672B-4A6E-943A-F2E6067574E7 Q34426673-5A0D998C-7E55-4746-8E92-046623C58D39 Q34499039-2391ADCA-377A-40E4-912D-FAAA2C973F2C Q34565398-E1DB1279-1582-462F-BCCB-EA405E09FBA5 Q34655792-96CB1800-9444-4C09-9781-254AB3295BC7 Q34851812-9350EB61-16E9-45BD-95F0-C9E6EAA0A858 Q35426181-0EC7928E-96E7-4DDC-8B08-0C6385F22146 Q35613265-D0C3E3AC-2E6B-4FD7-AA54-0E7FBFBA82F1 Q35636430-CC834F8A-17DA-40EB-AD8F-29D90842F387 Q35758411-DAA031D1-C1B0-4CA4-BF1A-1DE3035C8A3B Q35814862-026A8B21-0341-4EA1-8F6C-4512AD38A325 Q35845845-6D166AA6-7FCB-433C-B243-4C7506E9D047 Q35873871-8A53C867-2552-498F-9F6F-6B152D924922

P2860

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

http://www.wikidata.org/entity/Q44261800

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@en

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@nl

type

label

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@en

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@nl

prefLabel

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@en

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@nl

P1433

Q44261800-8940F4F9-666D-4610-8B49-D06C45E17839

P1476

Q44261800-1A5EDB23-8458-4756-913C-3AA313F13B9B

P2093

Q44261800-05700116-B934-42F8-961F-7ECADC2B38AC

Q44261800-11785B99-D42C-466B-AEB5-F1353B258D7D

Q44261800-22024601-6ED4-4A9F-8ADB-2637A97D084A

Q44261800-379DBC70-9674-4F46-A964-56B2BD93B3B0

Q44261800-5ABB71AA-F3C3-4179-BE3C-488489BA5CB3

Q44261800-890D2B85-D25F-4756-97F4-3B0A1CE05739

Q44261800-AFB9D297-F4CA-43D5-B25F-CD9EC63A66A8

Q44261800-B2D7D207-C6FF-45C7-94F0-FBB8472C0299

Q44261800-E9C5683A-7E86-495E-9B2C-43FD673D14C4

Q44261800-ED4FECB7-2AD5-4B54-836A-8D459BF23A39

P304

Q44261800-15A65A30-1786-4EF6-BB40-1EAD5F610B5A

P31

Q44261800-6612C6A5-9DA0-48CB-A484-3FEE7B42D564

P356

Q44261800-50C8875B-D4E4-411C-BEA4-6BFA995D88BE

P407

Q44261800-6FCC773B-DF1A-45D4-BAEA-1BB8FE27975F

P433

Q44261800-E9CF079F-938A-448B-BA1C-11086F75F7B4

P478

Q44261800-B3860679-90C3-4A80-A0C0-7990DDFE79D4

P50

Q44261800-BA814587-6313-462F-BF9B-797E739E9C49

P577

Q44261800-6DE93CF1-6B0A-49BC-9941-9E2FAD349738

P698

Q44261800-8E5BA113-5CE8-45EC-BA6F-06CC2A068DAB

P921

Q44261800-15A28CA0-E041-4B14-9933-65612E0BDF24

Q44261800-BCE682DD-5D54-4AB3-B6F3-7DDB3C88869E

P356

P1433

The New England Journal of Medicine

P1476

Celecoxib versus diclofenac an ...... ng in patients with arthritis.

@en

P2093

Aric J Hui

http://www.w3.org/2001/XMLSchema#string

Bing Y Suen

http://www.w3.org/2001/XMLSchema#string

Joseph J Y Sung

http://www.w3.org/2001/XMLSchema#string

Justin C Y Wu

http://www.w3.org/2001/XMLSchema#string

Ka F To

http://www.w3.org/2001/XMLSchema#string

Kenneth C Lee

http://www.w3.org/2001/XMLSchema#string

Lawrence C T Hung

http://www.w3.org/2001/XMLSchema#string

S C Sydney Chung

http://www.w3.org/2001/XMLSchema#string

Vincent K S Leung

http://www.w3.org/2001/XMLSchema#string

Vincent W S Wong

http://www.w3.org/2001/XMLSchema#string

P304

2104-2110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA021907

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Francis Ka-Ming Chan

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12501222

http://www.w3.org/2001/XMLSchema#string

P921